157 related articles for article (PubMed ID: 18504612)
1. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
Mystakidou K; Stathopoulou E; Parpa E; Kouloulias V; Kouskouni E; Vlahos L
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1303-10. PubMed ID: 18504612
[TBL] [Abstract][Full Text] [Related]
2. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
4. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
[TBL] [Abstract][Full Text] [Related]
5. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
McCormack PL; Plosker GL
Drugs; 2006; 66(5):711-28. PubMed ID: 16620148
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
7. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Francini F; Pascucci A; Bargagli G; Francini E; Conca R; Miano ST; Martellucci I; Migali C; Gotti G; Fiaschi AI; Cozzolino A; Petrioli R
Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
[TBL] [Abstract][Full Text] [Related]
10. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Nelson A; Fenlon D; Morris J; Sampson C; Harrop E; Murray N; Wheatley D; Hood K; Griffiths G; Barrett-Lee P
Trials; 2013 Oct; 14():325. PubMed ID: 24107437
[TBL] [Abstract][Full Text] [Related]
11. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.
Rizzoli R
Ann Oncol; 2004 May; 15(5):700-1. PubMed ID: 15111335
[No Abstract] [Full Text] [Related]
13. Oral ibandronic acid.
Gennari L
IDrugs; 2005 Feb; 8(2):155-69. PubMed ID: 15696417
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.
Kucukzeybek Y; Gorumlu G; Cengiz E; Karabulut B; Sezgin C; Atmaca H; Sanli UA; Uzunoglu S; Uslu R
J Int Med Res; 2010; 38(5):1663-72. PubMed ID: 21309480
[TBL] [Abstract][Full Text] [Related]
15. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
16. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
Pecherstorfer M
Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
19. Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
Yaman E; Benekli M; Coskun U; Ozturk B; Kaya AO; Yildiz R; Buyukberber S
Ann Oncol; 2008 Feb; 19(2):397-8; author reply 398. PubMed ID: 18260185
[No Abstract] [Full Text] [Related]
20. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
Pecherstorfer M
Expert Opin Pharmacother; 2008 Dec; 9(17):3111-9. PubMed ID: 19006482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]